FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations.

Pedro Luiz Serrano Uson JuniorThomas T DeLeonJames M BogenbergerRish K PaiHeidi E KosiorekJun YinDaniel H AhnMohammad Bassam SonbolTanios Bekaii-SaabAaron S MansfieldKenneth BuetowGregory J GoresRory SmootGeorge VasmatzisBenjamin R KippAmit MahipalAlexander T BakerHani BabikerOumar BarroChelsae DumbauldYumei ZhouFaaiq N AslamMichael BarrettBertram JacobsNathalie MeuriceMansi AroraJoachim PetitNatalie ElliottBolni NagaloMarcela A SalomaoMitesh J Borad

Published in: Digestive diseases and sciences (2021)

FGFR2 protein expression by immunohistochemistry has high specificity and therefore could be used to imply the presence of FGFR2 genomic alterations in the context of a positive test. In the case of a negative test, NGS or FISH would be necessary to ascertain cases with FGFR2 genomic alterations.

Keyphrases

copy number
poor prognosis
gene expression
dna methylation
long non coding rna